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Abstract
Short/branched chain acyl-CoA dehydrogenase (SBCAD) deficiency, also known as 2-
methylbutyryl-CoA dehydrogenase deficiency, is a recently described autosomal recessive
disorder of isoleucine metabolism. Most patients reported thus far have originated from a founder
mutation in the Hmong Chinese population. While the first reported patients had severe disease,
most of the affected Hmong have remained asymptomatic. In this study we describe 11
asymptomatic non-Hmong patients brought to medical attention by elevated C5-carnitine found by
newborn screening and one discovered because of clinical symptoms. The diagnosis of SBCAD
deficiency was determined by metabolite analysis of blood, urine, and fibroblast samples. PCR
and bidirectional sequencing were performed on genomic DNA from five of the patients covering
the entire SBCAD (ACADSB) gene sequence of 11 exons. Sequence analysis of genomic DNA
from each patient identified variations in the SBCAD gene not previously reported. E. coli
expression studies revealed that the missense mutations identified lead to inactivation or instability
of the mutant SBCAD enzymes. These findings confirm that SBCAD deficiency can be identified
through newborn screening by acylcarnitine analysis. Our patients have been well without
treatment and call for careful follow-up studies to learn the true clinical impact of this disorder.
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1.1 INTRODUCTION
The acyl-CoA dehydrogenases (ACADs) are a family of closely related mitochondrial
enzymes that catalyzes the removal of hydrogen atoms from the α and β positions (also
known as β-oxidation) of straight or branched chain acyl-CoA esters in the metabolism of
amino acids and fatty acids, transferring electrons to electron transferring flavoprotein [1–8].
At least 9 members of this family have been described so far. Short chain acyl-CoA
dehydrogenase (SCAD), medium chain acyl-CoA dehydrogenase (MCAD), long chain acyl-
CoA dehydrogenase (LCAD), very long chain acyl-CoA dehydrogenase (VLCAD), and
acyl-CoA dehydrogenase 9 (ACAD9) all catalyze oxidation of acyl-CoAs in mitochondrial
fatty acid β-oxidation. Human ACAD9 plays a unique role in the mitochondrial β-oxidation
of unsaturated fatty acids [9]. Glutaryl-CoA dehydrogenase is active in the lysine
degradation, while isovaleryl-CoA dehydrogenase, short branched chain acyl-CoA
dehydrogenase (SBCAD, also known as 2-methylbutyryl-CoA dehydrogenase), and
isobutyryl-CoA dehydrogenase (IBD, also designated ACAD8) function in the catabolism of
leucine, isoleucine, and valine intermediates, respectively [5,7,10–16]. SBCAD, like all
ACADs except VLCAD and ACAD9, is a homotetrameric mitochondrial enzyme catalyzing
alpha and beta dehydrogenation of acyl-CoA derivatives with greatest activity toward
straight/branched short chain acyl-CoA metabolites and specifically toward 2-methybutyryl-
CoA, catalyzing the third step of the isoleucine catabolic pathway [13].
Deficiencies in all of these enzymes except LCAD have been associated with human disease
[7,14,16–24]. SBCAD deficiency (OMIM 600301/610006) has only recently been
described. The first two patients were identified due to significant medical problems and
were shown to have SBCAD deficiency [16,25]. Subsequently, this disorder has been
shown, through population and newborn screening studies, to be common in individuals of
Hmong ancestry [26,27.] A minority of patients in the Hmong population diagnosed through
newborn screening was reported to have transient muscle hypotonia, but the Hmong patients
have otherwise been well. Additional non-Hmong patients with SBCAD deficiency have
also been identified through newborn screening and remain well, as have others diagnosed
through metabolic evaluations for clinical symptoms [26,28–30]. One patient was reported
to have autism and mental retardation, but causation could not be established [31]. Thus, the
significance of SBCAD deficiency remains unclear.
In this study we describe 11 patients from various medical centers identified by newborn
screening because of elevated C5-acylcarnitine levels. An additional patient who was born
before acylcarnitine analysis was added to the respective State’s newborn screening program
was identified during an evaluation for clinical symptoms. Further diagnostic testing,
including plasma acylcarnitines, plasma amino acids, urine organic acids, urine
acylglycines, and fibroblast acylcarnitine profiling, substantiated SBCAD deficiency in all
12 patients. Sequencing of genomic DNA from 5 patient fibroblasts identified mutations
predicted to be deleterious in four of the patients identified by newborn screening and in the
symptomatic patient. In vitro mutagenesis and expression studies of point mutations in E.
coli confirmed that they lead to an inactive or unstable SBCAD protein. Individuals detected
through newborn screening programs remain well with the oldest being 4 years old,
suggesting that this deficiency may be a biochemical phenotype rather than a disease.
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1.2 MATERIALS AND METHODS
1.2.1Urine Organic Acid, Acylglycine, and Acylcarnitine, Plasma Acylcarnitine, and
Fibroblast In Vitro Probe Analyses
Acylcarnitine analyses from dried blood spots, plasma, and urine samples, urine organic acid
and acylglycine analyses, and the in vitro probe assay in fibroblast cultures were performed
following established procedures [32].
1.2.2 Molecular Genetic Analysis
Molecular genetic analysis of the ACADSB gene was performed using genomic DNA
extracted from fibroblasts samples [16]. All 10 exons and 18 intron-exon junctions were
amplified by PCR and DNA analysis was performed by dye-terminator sequencing PCR-
amplified fragments on an Applied Biosystems 3730 DNA Analyzer (Foster City, CA) at the
University of Pittsburgh Genomics and Proteomics Core Laboratory. Primer sequences for
exon amplification and sequencing are available upon request.
1.2.3 Computational Molecular Modeling
Computational modeling and visualization of human SBCAD were performed on a Silicon
Graphics Fuel workstation (Mountain View, CA) using the Insight II 2005 software package
(Accelrys Technologies, San Diego, CA) and the published atomic coordinates of human
SBCAD (PDB code: 2JIF) (Pike, et al, 2007, GenBank entry).
1.2.4 SBCAD Mutagenesis and Expression
Patient mutations c.443C>T and c.1159G>A were introduced into a wild type SBCAD
expression vector with QuickChange II mutagenesis Kit (Stratagene, La Jolla, CA) and
expressed in E. coli as previously described [33]. The presence of SBCAD cross-reactive
material was then determined by western blot analysis of crude fibroblast extracts [34].
1.2.5 Enzyme Activity Assay
Enzyme activity was measured with the anaerobic electron transfer flavoprotein (ETF)
fluorescence reduction assay using an LS50B fluorescence spectrophotometer from
PerkinElmer Life Sciences (Wellesley, MA) with a heated cuvette block set to 32°C as
described [13]. Acyl-CoA substrates were purchased from Sigma (St. Louis, MO). The
reaction was started with the addition of the CoA ester substrate to give a final concentration
of 25 μM. Activity was calculated with one mU of activity defined as the amount of enzyme
necessary to completely reduce one nmol of ETF in one minute.
1.3 RESULTS
1.3.1 Clinical Summary
Eleven patients identified by newborn screening as having elevated C5-carnitine levels have
been further studied. All were confirmed to have persistently elevated C5-carnitine levels in
blood. Additional testing was variable but all either had elevation of 2-
methylburtyrylglycine in urine (with no intermediates consistent with isovaleric acidemia),
or an increase in 2-methylbutyrylcarnitine in culture medium from patient fibroblasts
incubated with deuterated isoleucine consistent with a diagnosis of SBCAD deficiency. All
of the newborn screening patients have been followed for up to three years, and all have
remained asymptomatic at the time of the manuscript preparation with the oldest being 4
years old.
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Information on the level of “C5-carnitine” reported on the initial newborn screen report was
available on 7 of 11 individuals. Because the samples were analyzed in several labs and
reported with different cutoffs, we have calculated the fold-increase over the lab-reported
maximum normal value to allow comparison. The differences ranged from a low of 1.1 fold
to >19 fold increase. C5-carnitine levels decreased with time on all patients with one falling
to the normal range. However, since all patients were asymptomatic, no correlations of
screening or follow up levels with phenotype were possible. While the asymptomatic
patients likely represent all screen positive babies from the respective states of residence of
the co-authors of this study, a formal determination of incidence was not made.
One final individual, a 3½-year-old girl, was found to have an elevated plasma C5-carnitine
during metabolic evaluation for clinical disease. She was the product of non-
consanguineous, European ancestry, born by elective C-section at term with a birth weight
of 2,358 g. She had a normal neonatal course and good general health. She was born prior to
acylcarnitine analysis being added to her birth state’s newborn screening program. Concerns
regarding her development arose when she did not crawl at about eight month of age.
Subsequently her gross motor development was noted to be delayed; she walked at the age
of two years and climbed stairs at the age of 3 ½ years. Speech and language were delayed.
At the age of 3 ½ she was also noted to show balance problems with poor coordination and
abnormal wide based gait with ataxia. Since the age of 1 year she demonstrated sleep
disturbance and staring episodes as well as behavioural issues including head banging. She
was described as an interactive girl with good socializing skills. On examination at 3 ½
years of age she had dysmorphic features including microcephaly (head circumference 46.5
cm; <3), wide set eyes with prominent nasal bridge, prominent but low set ears and
micrognathia, and blond and brittle hair. There were no skeletal abnormalities and no
organomegaly. Her neurological exam revealed that she was unable to speak and was not
able to understand complex commands; cranial nerves were intact. Tone was reduced but
muscle bulk was normal and deep tendon reflexes were brisk. MRI scan of the brain showed
simplified general pattern with decreased cortical sulci most likely representing brain
dysgenesis, MRS was normal. EEG revealed abnormal right temporal inter-ictal discharges
consistent with a partial seizure disorder. Chromosome and fragile X testing were normal, as
was sequencing of exons 2 and 3 of the MECP2 gene. Her plasma amino acids were normal
as were chromosomes, Angelmann syndrome testing and microarray analysis. Urinary
organic acid analysis revealed methylbutyryglycine in the urine (amount not quantified).
Molecular analysis showed the patient to be homozygous for the intron 3 +1 G>A mutation
also identified in one of the asymptomatic infants identified through newborn screening.
1.3.2 SBCAD Gene Analysis
Bidirectional sequence analysis of genomic DNA from 4 of the newborn screening patients
and the one symptomatic individual has identified two variations in the ACADSB gene not
previously reported and two previously described mutations (Table 1). The first was
homozygous for a c.295C>T mutation in exon 3 that introduces a stop codon in the coding
sequence (p.Gln99X). The patient’s parents are first cousins of Indian descent. No further
studies were performed on this early nonsense mutation since only a short, unstable piece of
the protein is likely to be produced. The second patient identified by newborn screening (of
European ancestry) was a compound heterozygote for two previously described mutations,
c.443C>T (p.Thr148Ile) in exon 4 and c.1159G>A (p.Glu387Lys) in exon 10 [28,30]. An
additional exon 1 sequence variant (c.50G>A, p.R13K) was detected in individual 2. This is
a conservative substitution in the mitochondrial targeting signal and is not predicted to affect
function. Moreover, it is polymorphic in the population as determined though the HapMap
Project website (www.hapmap.org) with heterozygote G/A frequency in Nigerian Africans
of 22.4%, Japanese 22.2% and Chinese 13.3%. One asymptomatic and one symptomatic
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patient were homozygous for a G>A mutation at the +1 position of the splice donor site for
intron 3 that disrupts the canonical splicing signal for that intron. A mutation affecting this
intron has previously been described [35]. This is predicted to be a null mutation and so no
mutagenesis assay was performed. An additional baby identified through newborn screening
had a fibroblast acylcarntine profile consistent with complete SBCAD deficiency, but only
one heterozygous nonsense mutation was identified in exon 5 genomic DNA. cDNA was
homozygous for the mutation in this region indicating that the mutation on the second allele
must either result in loss of transcription of the SBCAD gene, an unidentified intronic
mutation that results in abnormal splicing and/or unstable RNA, or deletion of part of the
allele containing the normal exon 5 sequence. Unfortunately, samples for gene sequencing
were not available for the rest of the patients identified through newborn screening.
1.3.3 Computational and Functional Analyses
To examine the possible effects of the identified mutations on SBCAD structure, we
modeled each point mutation into the published three dimensional structure of the protein
(Figure 1A). The computational molecular modeling suggested that a Thr148Ile substitution
might be tolerated, however, the Thr148 residue lies in a hydrophilic pocket, where an Ile
replacement could also be disruptive (Figure 1B. In contrast, the Glu387Lys mutation is
predicted to be deleterious to enzyme quaternary structure, disrupting a hydrogen bonding
conduit that includes residues Arg384:Glu387:Thr411’ (the prime designation for residues
from the second subunit) that is likely essential for monomer-monomer binding (Figure 1B).
The mutation would also disrupt FAD binding, deleterious to enzyme stability, since the
Glu387 backbone oxygen directly binds an FAD hydroxyl group. To investigate these
hypothetical effects experimentally, in vitro mutagenesis was used to introduce each
mutation into a prokaryotic expression vector for SBCAD. For both mutations, western blot
analysis of E. coli cell extract following expression of vectors containing each mutation
identified no detectable cross reactive material to SBCAD antigen (Figure 2), and no
enzyme activity was measurable in the cellular extract, indicating that the protein folding
and/or stability were grossly affected (Table 2).
1.4 DISCUSSION
1.4.1 Clinical Findings in SBCAD Deficiency
In this report, we present 11 non-Hmong infants with SBCAD deficiency identified through
newborn screening. To date all have been well, which is in striking contrast to the dramatic
phenotype previously reported in the first patients found to have this disorder, as well as the
ones identified in this study [16,25,31]. The first reported patient presented with acute
metabolic acidosis at three days of age after an uncomplicated pregnancy and delivery, and
then exhibited chronic seizures, abnormal movements, and developmental delay [16]. His
sister was subsequently diagnosed prenatally and has not had any episodes of metabolic
decompensation while maintained on a low protein diet. Other individuals identified on
evaluation for possible metabolic conditions have presented with a constellation of chronic
neurologic symptoms including seizures, developmental delay, hypotonia, recurrent
vomiting and attention deficit disorder [25,29,30]. In contrast, all reported patients detected
through newborn screening with an elevated C5 carnitine, including this study, have
remained asymptomatic [26–30]. It is hard to reconcile the clinical differences demonstrated
between these groups of patients. SBCAD deficiency may well have predisposed the
symptomatic individuals to neurologic damage with or without acute acidosis but the
increasing number of asymptomatic patients identified through newborn screening and
family studies suggests the original association may have been coincidental. Notably, our
one patient identified through an evaluation for significant symptoms had the same SBCAD
mutation as an asymptomatic newborn. In addition the symptomatic patient had findings
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suggestive of a primary neuronal migration defect. Thus, it is likely that the SBCAD
deficiency is irrelevant to the patient’s clinical picture.
One group of SBCAD deficient patients deserves special mention. The Hmong are a
population of ethnic Chinese that migrated first to Southeast Asia and, more recently, to the
US. Not surprisingly, a recurrent point mutation has been identified in the SBCAD coding
region in this population [27]. Several of these patients initially had mild hypotonia, but this
resolved over time. Additional numerous deficient individuals in this population have since
been identified through newborn screening or family studies, and they have been essentially
asymptomatic with normal development [27].
1.4.2 Newborn Screening and Variable Phenotypes
Organic acidemias were originally recognized as severe, life threatening inborn errors of
metabolism that ultimately led to acute episodes of metabolic decompensation with acidosis
and often death. This is typified by the classic description of neonatal onset isovaleric
acidemia [36]. In contrast, disorders of mitochondrial β-oxidation are more generally
recognized as more variable and often conditional [17,18]. That is, patients may be well for
long periods of time, even life long, and only manifest symptoms when under common
stress such as intercurrent illness. This distinction is being blurred by the increased
recognition of mild forms of organic acidemias by expanded newborn screening.
Deficiencies of the acyl-CoA dehydrogenases offer a good example of this phenomenon.
Newborn screening has now led to the identification of individuals with increased
isovaleryl-CoA derivatives in blood and urine and a common mutation in the IVDH gene
leading to reduction of isovaleryl-CoA dehydrogenase activity [15,37]. All of these patients
have remained well through at least 10 years of age. Other individuals with complete IVDH
deficiency have remained well with dietary restrictions, albeit some have had episodes of
intermittent metabolic acidosis. A very similar story has become evident for short chain
acyl-CoA dehydrogenase deficiency [24]. The first reported patient with this latter disorder
died of overwhelming neonatal acidosis, however, numerous asymptomatic individuals have
now been identified through newborn screening. While the clinical risks related to SBCAD
and other ACAD deficiencies now appear to be less than originally thought, it would be
imprudent to disregard them completely. Rather, long term studies will be necessary to
assess the true risk of acute and chronic disease in these patients.
1.4.3 Diagnosis of SBCAD Deficiency and Follow-up of Abnormal Newborn Screens
Regardless of the clinical significance of SBCAD deficiency, the need to unequivocally
identify it is clear since it is now most frequently suspected on the basis of newborn
screening results. Under these circumstances, it is crucial to differentiate it from isovaleric
acidemia as isovaleryl- and 2-methylbutyrylcarnitine share the same mass/charge ratio (m/z
302 on a precursor of 85 scan) [26,30,38]. While fibroblast enzyme and acylcarnitine studies
or molecular analysis serve this function, the unavoidable delay in diagnosis would be
unacceptable. Fortunately, in analogy to the multiple alternative metabolites that accumulate
in isovaleric acidemia, additional metabolites can also be identified in SBCAD deficiency.
2-methylbutyrylglycine and/or 2-methylbutyrylcarnitine may be increased in urine but may
also be normal [26,30,38]. 2-Ethylhydracrylic acid (2-EHA) present in blood due to
catabolism of isoleucine by the alternative R-pathway can be a sensitive though not specific
marker for SBCAD deficiency [30]. Three other disorders also accumulate 2-EHA in blood:
β-ketothiolase, ethylmalonic encephalopathy, and Barth syndrome, though other metabolites
distinguish these disorders from SBCAD deficiency [28,30,39–42]. It is important to note
that although the C5-carnitine level has been reported to be within the normal range in some
SBCAD deficient patients, all of the patients reported in this study had elevated levels of
this metabolite on newborn screen. However, in one patient, the level normalized on
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subsequent evaluation (Table 2). In recognition of these issues, the American College of
Medical Genetics ACT sheets for response to the finding of elevated C5-carnitine on a
newborn screen advocates urine organic acid and acylglycine determination as the initial test
following an abnormal newborn screening result
(http://www.acmg.net/resources/policies/ACT/condition-analyte-links.htm).
1.4. 4 Therapy
The need for and type of therapy in SBCAD deficiency is unclear. The therapeutic approach
in initial cases included a low protein diet, avoidance of fasting, and carnitine
supplementation [29]. However, the Hmong patients with SBCAD deficiency identified
through family studies have remained asymptomatic as have all previously reported infants
identified by newborn screening [27]. In light of this observation, disruptive dietary
manipulations for infants identified by newborn screening are of questionable indication.
Rather, it would seem more prudent to continue a normal diet in these infants but also have
the family maintain some level of vigilance during intercurrent illnesses. Additional long
term studies will be necessary to address this issue
1.5 CONCLUSIONS
We present 11 non-Hmong patients with SBCAD deficiency identified through newborn
screening acylcarnitine analysis. The lack of clinical symptoms in these patients in
conjunction with similar findings in a high risk population (the Hmong Chinese) emphasizes
the need to further evaluate the clinical relevance of this biochemical disorder. Rare
symptomatic patients may represent the extreme (and unusual) end of the clinical spectrum
or coincidental findings. Thus additional diagnostic testing is required to make a definitive
diagnosis in infants who screen positive. Consequently, long term follow up of these patients
will be critical to addressing the phenotypic spectrum of SBCAD deficiency.
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Figure 1.
Ribbon representation of point mutations identified in SBCAD gene. A. The tetrameric
SBCAD crystal structure, PDB code 2JIF, is shown with each subunit colored a different
color. FAD is shown as yellow and bound substrate as green. The amino acid substitutions
identified in this and other studies are represented as yellow balls with precursor protein
numbering given. Leu255Phe and Ser368Pro have previously been reported in Korman, et
al, 2005). The former is likely to be important in stabilizing the interaction between two
adjacent alpha helices. Ser368 likes in an alpha helix that is likely to have its trajectory
altered by substitution of a proline. B. Residues at the 148 and 387 positions (precursor
numbering) are illustrated. The Thr148 hydroxlate group lies in a hydrophilic pocket, but
does not directly interact with other residues side chains. The carboxylate oxygen molecules
of Glu387 lie between the Lys384 side chain amino group and the hydroxyl group of
Thr411’ of the second subunit forming a hydrogen bonding conduit. In addition, the Glu387
backbone oxygen is directly involved in FAD binding through hydrogen bonding.
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Figure 2.
Western blotting of an SDS-PAGE gel of expressed SBCAD patient point mutations. The
arrow shows the migration position of purified recombinant SBCAD. Wild type SBCAD
expressed in E. coli yields a high level of SBCAD antigen in crude cell extracts. The
Glu387Lys and Thr148Ilu are minimally or not detectable.
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Table 1
Mutations identified in the ACADBS gene in patient cell lines
Mutation Presentation Treatment
Follow up “C5
carnitine” nM/ml
(normal range for
lab) Outcome
Homozygous c.295 C>T in exon 3 (p.Gln99X,
precursor protein)
Detected on NBS,
asymptomatic
None 0.88 (<0.8) No symptoms
Heterozygous c.443C>T in exon 4 (p.Thr148Ile,
precursor protein)
Heterozygous c.1159 G>A in exon 10 (p.E387K,
precursor protein)
Detected on NBS,
asymptomatic
None 1.89 (<0.63) No symptoms
Heterozygous c.50G>A, p.R13K
Heterozygous c621G>A in genomic DNA (W207X,
precursor protein)
Detected on NBS,
asymptomatic
None 0.25 (0.33) No symptoms
Homozygous for this mutation in cDNA
Homozygous IVS3+1G>A Detected on NBS,
asymptomatic
None 2.58 ((<.63) No symptoms
Homozygous IVS3+1G>A 4 year old Developmental
delay, dysmorphic
features
None 1.47 (<0.38) Developmental
delay, simplified
brain sulci pattern,
microcephaly
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Table 2
Activity of Wild type and mutant SBCADH expressed in E. coli
Vector Activity (mU/mg cellular protein; % wild type)
Wild type 25; 100%
c.443C>T 0.7; 2.8%
c.1159G>A 0.5; 2.0%
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